Login to Your Account

In the clinic

Friday, January 12, 2018

Forty Seven Inc., of Menlo Park, Calif., said it inked a deal with Darmstadt, Germany-based Merck KGaA to conduct a phase Ib trial combining CD47-targeting candidate Hu5F9-G4 with PD-1/PD-L1-targeting Bavencio (avelumab) in patients with ovarian cancer.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription